Latest Infinity Pharmaceuticals Stories
Informative webinar will explore strategic alliances through a case study of the relationship between Infinity Pharmaceuticals and INC Research.
Infinity Pharmaceuticals, a cancer drug discovery and development company, has announced that it has met pre-specified criteria to expand both arms of its ongoing Phase II clinical trial evaluating IPI-504, its lead heat shock protein 90 inhibitor, in patients with advanced non-small cell lung cancer.
Infinity Pharmaceuticals, a cancer drug discovery and development company, has announced preclinical data demonstrating anti-tumor activity with IPI-493, the company's oral heat shock protein 90 inhibitor.
Infinity Pharmaceuticals has initiated a Phase I clinical trial of IPI-493, its oral anti-chaperone agent, in patients with advanced solid tumors. The multi-center, Phase I study of oral IPI-493 is designed as a dose-escalation trial in patients with advanced solid tumors.